Replies to post #71945 on Biotech Values

[DewDiligence]

Re: Reg FD / RPRX

Sorry, I wasn't trying to make a legal comment regarding Reg FD. I was trying to be more practical in suggesting that an investor can contact the company and ask for the data.

How is an investor supposed to know that there is information to be had beyond what’s detailed in a company press release announcing the clinical results?

Regardless, along the lines of your point, the response of the company to an inquiry will tell much about their corporate professionalism. If they don't release the data, does an investor really want to spend any more time following such a company?

Whether they do or don’t release the data in question in reply to a phone inquiry, there is still a Reg FD problem for the reasons already mentioned. More important, the latest Proellex PR is intentionally misleading and seeks to conceal, among other things, the high dropout rate in the Proellex arms. In short, RPRX does not pass the smell test on a number of criteria.